StockData

Ligand Pharmaceuticals vs MacroGenics

LGND and MGNX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How LGND and MGNX compare

Ligand Pharmaceuticals is the larger company, worth 45 times as much as MacroGenics ($5.9B against $131M).

MacroGenics grew revenue faster over the last twelve months (11.7% versus 1.0% for Ligand Pharmaceuticals).

Ligand Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 20.3% compared with −8.7% at MacroGenics.

Ligand Pharmaceuticals scores higher on the StockData Score (6 against 5 for MacroGenics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricLGNDMGNX
Size and price
Market cap$5.9B$131M
Share price$293.81$2.05
Change, 1 year46.3%36.7%
Change, 5 years87.3%−89.1%
Beta (5Y)0.840.53
Employees47293
StockData Score
Total score6 (better)5
Valuation score00
Growth score11
Performance score33
Health score2 (better)1
Dividend score00
Valuation
P/E128×–
P/S23.2×0.8× (better)
P/B6.1×3.0× (better)
EV/EBITDA108×–
P/FCF64.8×–
FCF yield1.5% (better)−50.2%
Fair value$55.15–
Margin of safety−433%–
Growth
Revenue growth (TTM)1.0%11.7% (better)
Revenue growth, 5Y average10.4% (better)7.3%
Net income growth (TTM)5.9%–
EPS growth (TTM)18.7%–
Profitability
Operating margin10.1% (better)−24.3%
Net margin20.3% (better)−8.7%
FCF margin35.7% (better)−39.1%
Return on equity5.4% (better)−32.6%
Return on invested capital2.6%–
Financial health
Debt / equity1.17–
Net debt / EBITDA11.26–
Interest coverage3.1× (better)−2.4×
Current ratio1.222.96 (better)
Altman Z-score3.32 (better)−4.02
Piotroski F-score6 (better)4
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions113%76.4%
Held by insiders2.6%6.2%
Insider net buying, 12 months−$36.5M−$129K (better)
Short interest, % of float–8.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.